Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: US Rare Earth Minerals Inc

Market Cap 34.58L 29.78L 27.41L 25.75L 48.38L 33Cr 48.91L 3.24Cr 1.26Cr 16Cr 1.3Cr 1.27Cr 55Cr P/E Ratio 2024
-5.27x
P/E Ratio 2025 -3.28x
Enterprise Value 41.99L 36.15L 33.28L 31.27L 58.74L 40Cr 59.39L 3.93Cr 1.53Cr 19Cr 1.58Cr 1.54Cr 67Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.38%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 73 01/09/2018
Director of Finance/CFO 65 01/09/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 02/11/2018
Director/Board Member 73 02/11/2018
Chairman 73 01/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-0.97%+50.38%+109.48% 5.49TCr
-1.22%+2.25%+43.78%+38.45% 4.43TCr
-1.43%+4.68%-16.02%-20.80% 2.3TCr
-1.99%+1.43%-3.25%+377.36% 2.11TCr
-2.91%-1.18%+7.21%-36.53% 1.63TCr
-2.38%-3.41%+5.06%-40.72% 1.52TCr
-1.70%+0.70%+25.27%+172.77% 1.33TCr
+1.48%+11.36%+22.59% - 1.25TCr
+4.10%+7.02%+104.41%+226.33% 1.12TCr
Average -0.75%+2.67%+26.61%+103.29% 2.35TCr
Weighted average by Cap. -0.99%+2.01%+29.52%+94.48%

Financials

2024 2025
Net sales - -
Net income -23.67L -20.38L -18.76L -17.63L -33.11L -22Cr -33.47L -2.21Cr -86.32L -11Cr -88.81L -86.92L -38Cr -21.23L -18.28L -16.83L -15.81L -29.7L -20Cr -30.03L -1.99Cr -77.43L -9.83Cr -79.67L -77.97L -34Cr
Net Debt 10.89L 9L 9L 8L 15.24L 10Cr 15.4L 1.02Cr 39.71L 5.04Cr 40.86L 39.99L 17Cr 7L 6L 6L 6L 10.36L 7.01Cr 10.48L 69.33L 27.02L 3.43Cr 27.8L 27.21L 12Cr
Logo US Rare Earth Minerals Inc
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!